Search General Info
Search Education
Search Partnering Companies

Christopher Arendt

Chris Arendt is the Head of the Oncology Therapeutic Area Unit at Takeda Pharmaceutical Company Limited and a member of the R&D Management Committee (RMC). In his role, he has overall responsibility for the oncology R&D strategy, development portfolio goals and budget. The therapeutic area unit consists of clinical, program leadership, and program and portfolio management functions. Dr. Arendt has matrix leadership responsibility for all development programs from candidate selection through lifecycle management, via cross-functional program teams.

Dr. Arendt has been a key architect in the shaping of Takeda’s emerging immuno-oncology strategy and portfolio. He previously served as Head of Takeda’s Oncology Drug Discovery Unit & Immunology Unit. In this role, he worked collaboratively to establish key partnerships and oversee the execution of several research programs of I-O assets that are now, or soon to be, in the clinic.

Prior to joining Takeda, Dr. Arendt spent more than 13 years at Sanofi, where he led teams advancing novel immunotherapies for cancers and inflammatory diseases to the clinic.

Dr. Arendt received his Ph.D. in immunology from the University of Alberta. He completed his postdoctoral training at the Skirball Institute of Biomolecular Medicine at NYU Medical Center, supported by the Medical Research Council of Canada and Howard Hughes Medical Institute.
Speaking In
12:00 PM - 12:45 PM (EDT)
Wednesday, June 16

Collaboration among industry stakeholders is essential to discovering and developing emerging I…